medigraphic.com
Asociación Mexicana de Gastroenterología

2007, Number 3

<< Back

Rev Gastroenterol Mex 2007; 72 (3)

Treatment

Abdo-Francis JM

Language: Spanish
References: 101
Page: 332-338
PDF size: 109.67 Kb.


Text Extraction

No abstract


REFERENCES

  1. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, Grahan D, Hunt R, et al. The European Helicobacter Study Group (EHSG). Current concepts in the management of Helicobacter pylori infection: The Maastrich III Consensus Report. Gut 2007; 56: 772-81.

  2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175-86.

  3. Fennerty B. Helicobacter pylori: Why it still matters in 2005. Clev Clin J Med 2005; 72: S1-S8.

  4. Barddhan PK. Epidemiological features of Helicobacter pylori infection in developing countries. Clin Infect Dis 1997; 25: 973-8.

  5. Calva Rodríguez R, Luna Alcántara J, Lagunes-Yannelli B, Rivera-Domínguez ME, Calva-Cerqueira D, Santos-Marcial E. Prevalencia de infección por H pylori en tres poblaciones de niños de la Ciudad de Puebla, México y sus factores de riesgo. Rev Gastroenterol Mex 2006; 4: 440-5.

  6. Torres J, Leal-Herrera Y, Pérez-Pérez G, Gómez A, Carmolinga-Ponce M, Cedillo-Rivera R, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998; 178: 1089-94.

  7. Torres J, López L, Muñoz O. Trends in Helicobacter pylori infection and gastric cancer in Mexico. Cancer Epidemiol Biomarkers Prev 2005; 14: 1874-7.

  8. Eslick GD, Lim LLY, Byles JE, Xia HHX, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis. Am J Gastroenterol 1999; 94: 2373-9.

  9. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.

  10. Fischbac W, Dragosics B, Kolve-Goebeler ME, Ohmann C, Greiner A, Yang Q, et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000; 119: 1191-202.

  11. Zúñiga-Noriega JR, Bosques-Padilla FJ, Pérez-Pérez GI, Tijerina-Menchaca R, Flores-Gutiérrez JP, Maldonado-Garza HJ, et al. Diagnostic utility of invasive tests and serology for the diagnosis of Helicobacter pylori infection in different clinical presentations. Arch Med Res 2006; 37: 123-8.

  12. Bosques-Padilla FJ, Tijerina-Menchaca R, Pérez-Pérez GI, Flores-Gutiérrez P, Garza-González E. Comparison of Helicobacter pylori prevalence in symptomatic patients in Northeastern Mexico with the rest of the Country. Arch Med Res 2003; 34: 60-3.

  13. Personnet J, Shmueley H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. JAMA 1999; 282: 2240-5.

  14. Goodman KJ, Corea P, Tengana Aux HJ, Ramirez H, DeLany JP, Guerrero Pepinosa O, et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996; 144: 90-9.

  15. Ilver D, Arnqvist A, Ogern J, Frick IG, Kersulyte D, Incecik ET, et al. Helicobacter pylori adhesion binding fucosylated histo-blood group antigens revealed by retagging. Science 1998; 279: 373-7.

  16. Salama NR, Otto G, Tompkins L, Falkow S. Vacoulating cytotoxin of Helicobacter pylori plays a role during colonization in a mouse model of infection. Infect Immun 2001; 69: 730-6.

  17. Cesini S, Lange C, Xiang Z, et al. Cag A pathogenicity island of Helicobacter pylori, ecodes type I-specific and disease associated virulence factors. Proc Natl Acad Sci USA 1996; 93: 14648-53.

  18. Yamaoka Y, Kita M, Kodama T, Sawai N, Inamishi J. Helicobacter pylori cagA gene and expression of cytokine messenger RNA in gastric mucosa. Gastroeneterology 1996; 110: 1744-52.

  19. Fan X, Gunasena H, Cheng Z, et al. Helicobacter pylori urease binds to class II MHC on gastric epithelial cells and induces their apoptosis. J Immunol 2000; 165: 1918-24.

  20. Garza-Gonzalez E, Bosques-Padilla JF, Perez-Perez, Flores-Gutierrez JP, Tijerina-Menchaca R. Association of gastric cancer, HLA DQA1, and infection with Helicobacter pylori Cag A + and Vac A + in a Mexican population. J Gastroenterol 2004; 39: 1462-4.

  21. Herrera-Goepfert R, Yamamoto-Furusho JK, Oñate-Ocaña LF, Camorlinga-Ponce M, Muñoz L, Ruiz-Morales JA, Vargas-Alarcón G, Granados J. Role of the HLA-DQ locus in the development of chronic gastritis and gastric carcinoma in mexican patients. World J Gastroenterol 2006; 12: 7762-67.

  22. Torres J, Pérez-Pérez GI, Leal-Herrera Y, Muñoz O. Infection with CagA + Helicobacter pylori strains as a possible predictor of risk of gastric carcinoma in Mexico. Int J Cancer 1998; 78: 298-300.

  23. Atherton JC, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in Vac A, the vacuolating cytotoxin gene of Helicobacter pylori. Gastroenterology 1997; 112: 92-9.

  24. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-31.

  25. Eslick GD. Association of Helicobacter pylori Infection with Gastric Carcinoma: A Meta-Analysis. Am J Gastroenterol 1999; 94: 2373-9.

  26. Tsukamoto T, Mizoshita T, Tatemtsu M. Animals models of stomach carcinogenesis. Toxicol Pathol 2007; 35: 636-48.

  27. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez L, Halperin D, Ley C, Parsonnet. Gastric atrophy and extent of intestinal metaplasia in a cohort of Helicobacter pylori-infected patients. Hum Pathol 2001; 32: 31-5.

  28. Ohkusa T, Fujiki K, Takashimizu I, Kumagai J, Tanizawa T, Eishi Y, et al. Improvement in Atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 2001; 134: 386.

  29. McColl K, Murray L, El-Omar E, Dickson A, Adil El-Nujumi BA, Wirz A, et al. Symptomatic benefit from eradicating Helicobacter pylori in patients with nonulcer dispepsia. N Engl J Med 1998; 339: 1869-74.

  30. Blum AL, Talley NJ, O’Morain C, Veldhuyzen van Zanten S, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with non-ulcer dyspepsia. N Engl J Med 1998; 339: 1875-81.

  31. Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Syst Rev 2001; 1: CD002096.

  32. Laine L, Schoenfield P, Fennerty B. Therapy for Helicobacter pylori in patients with non-ulcer dyspepsia. Ann Int Med 2001; 134: 361-9.

  33. Kuipers EJ, Thies JC, Fasten HPM. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 1995; 9: 59-69.

  34. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic test in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 848-63.

  35. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267-71.

  36. Bayerdorffer E, Neubauer A, Rudolph B, Thiede C, Lehn N, Eidt S, Stolte M, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 1995; 345: 1591-4.

  37. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, Ye H, Molina T, Bouhnik Y, et al. Resistence of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.

  38. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003; 17: 297-305.

  39. Graham DY. The changing epidemiology of GERD: Geography and Helicobacter pylori. Am J Gastroeneterol 2003; 98: 1462-70.

  40. McColl KE, Dickson A, El-Nujuni A, El-Omar E, Kelman A, et al. Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 101-5.

  41. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.

  42. Malfertheiner P, Dent J, Zeijlon L, Sipponen P, Van Zanten V, Burman SJO, et al. Impact of H pylori eradication on heartburn in patients with gastric or duodenal ulcer disease-results from randomized trial program. Aliment Pharmacol Ther 2002; 16: 1431-42.

  43. Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121: 1120-6.

  44. Noguiera-de Rojas JR, Jiménez-González A, Cervantes-Solís C. La infección gástrica por Helicobacter pylori es un factor de protección para la enfermedad por reflujo gastroesofágico. Rev Gastroenterol Mex 2002; 67: 22-27.

  45. Carmona-Sánchez R, Navarro-Cano G. La prevalencia de infección por H pylori en pacientes con esofagitis por reflujo: estudio de casos y controles. Rev Gastroenterol Mex 2003; 68: 23-28.

  46. DuBois S, Kearny DJ. Iron-deficiency anemia and Helicobacter pylori infection: vba review of the evidence. Am J Gastroenterol 2005; 100: 453-9.

  47. Gasbarrini A, Franceschi F, Tartaglione R, Gasbarrini A, Landolfi R, Pola P, et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352(9131): 878.

  48. Franchini M, Veneri D. Helicobacter pylori infection and immune thrombocytopenia purpura: an update. Helicobacter 2004; 9: 342-6.

  49. Estrada-Gomez RA, Parra-Ortega I, Martinez-Barreda C, Ruiz-Argüelles GJ. Helicobacter pylori infection and thrombocitopenia: A single-institution experience in Mexico. Rev Invest Clin 2007; 59: 112-15.

  50. Schenk BE, Kuipers EJ, Nelis GF, Bloemena E, Thijs J, Snel P, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46: 615-21.

  51. Huang JQ, Shridhar S, Hunt RH, et al. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.

  52. Chan FK, Chung SC, Suen BY, et al. Eradication of Helicobacter pylori and the risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomized trial. Lancet 2000; 359: 9-13.

  53. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-18.

  54. Chan FK, Chung SC, Suen BY, Lee YT, Leung WK, Leung WK. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-73.

  55. Lai KC, Lam SK, Chu KM, Wong BCY, Hui WM. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-8.

  56. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 2330-38.

  57. Talley N, Vakil NB, Moayyedi P. American Gastroenterological Association technical review: evaluation of dyspepsia. Gastroenterology 2005: 129: 1753-5.

  58. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastro-esophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200.

  59. Weston AP, Campbell DR, Hassanein RES, Dixon A, McGregor DH. Prospective multivariate evaluation of CLOTest performance. Am J Gastroenterol 1997; 92: 1310-14.

  60. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 848-63.

  61. Gisbert JP, Pajares JM. 13C-urea breath test in the management of Helicobacter pylori infection. Dig Liv Dis 2005; 37: 99-906.

  62. Bravo LE, Realpe JL, Campo C, Mera R, Correa P. Effects of acid suppression and bismut medications on the performance of diagnostic tests for Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 2380-3.

  63. Malfertheiner P, Megraud F, O’morain C, Hungin APS, Jones R, Axon A, et al. Current concepts in the management of Helicobacter infection-The Maastrich 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 12: 167-70.

  64. Perri F, Manes G, Neri M, et al. Helicobacter pylori antigen stool test and 13C urea breathe test in patients after eradication treatments. Am J Gastroenterol 2002; 97: 2756-62.

  65. Tytgat GN. Treatment of peptic ulcer. Digestion 1998; 59(5): 446-52.

  66. Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: Infections in adults. Can J Gastroenterol 1999; 13: 213-7.

  67. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338(8776): 1175-6.

  68. Lee SK, Lee YC, Chung JB, Chon CY, Moon YM, Kang JK, et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: Treatment strategies based on 10 year follow-up. World J Gastroenterol 2004; 10(2): 223-6.

  69. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-8.

  70. Hojo M, Miwa H, Ohkusa T, Ohkura A, Sato N. Alteration of histological gastritis alter cure of Helicobacter pylori infection. Aliment Pharmacol Ther 2002; 16: 1923-32.

  71. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, Snel P, Goldfain D, Kolkmanet JJ, et al. Cure of Helicobacter pylori infection in patients with reflux esophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomized controlled trial. Gut 2004; 53: 12-20.

  72. Metz DC, Kroser JA. Helicobacter pylori and gastroesophageal reflux disease. Gastroenterol Clin North Am 1999; 28: 971-85.

  73. Sharma P, Vakil N. Review article: Helicobacter pylori and reflux disease. Aliment Pharmacol Ther 2003; 17: 297-305.

  74. Zapata-Colindres JC, Zepeda-Gómez S, Montaño-Loza A, Vazquez-Ballesteros E, Villalobos JJ, Valdovinos-Andraca F. The association of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic ulcer disease. Can J Gastroenterol 2006; 20: 277-80.

  75. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomized controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter eradication for lesion prevention. Lancet 1998; 352: 1016-21.

  76. Vergara M, Catalan M, Gisbert JP, Calvet X. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005; 21: 1411-18.

  77. Ciacci C, Sabbatini F, Cavallaro R, Castiglione F, Di Bella S, Iovino P, et al. Helicobacter pylori impairs iron absorption in infected individuals. Dis Liver Dis 2004; 36: 455-60.

  78. De la Torre BA. Papel de la Endoscopia. En: Bernal RR, Stoopen RM, De la Torre BA, Aguirre GJ. Gastritis. Programa de Actualización Continua en Gastroenterología. Libro 3, 2002, p. 133-145.

  79. Spiegel BM, Vakil NB, Ofman JJ. Dyspepsia management in primary care: a decision analysis of competing strategies. Gastroenterology 2002; 122: 1270-85.

  80. Chiba N, Van Zanten SJ, Sinclair P, Ferguson A, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomized controlled trial. BMJ 2002; 324: 1012-16.

  81. López-Vidal Y, Rangel-Frausto MS, Calva JJ. Resistencia a antimicrobianos de Helicobacter pylori en un centro de referencia infectológico. Rev Invest Clin 1998; 50(1): 19-24.

  82. Torres J, Carmolinga-Ponce M, Pérez-Pérez G, Madrazo-De la Garza A, Dehesa M, González-Valencia G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39(7): 2677-80.

  83. Megraud F, Hazell S. Antibiotic susceptibility and resistance. In: Helicobacter pylori: physiology and genetics. Washington, DC: ASM Press; 2001, p. 511-30.

  84. Megraud F. H. pylori antibiotic resistance: prevalence, importance and advances in testing. Gut 2004; 53: 1374-84.

  85. Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep 2005; 7: 115-20.

  86. Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice daily 10 day triple therapy with esomeprazole, amoxicillin and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double blind, Unites Sates trials. Am J Gastroenterol 1998; 93: 2106-12.

  87. Lind T, Van Zanten S, Unge P, Spiller R, Bayerdörffer E, O’Morain C, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1996; 1: 138-44.

  88. Fennerty MB, Kovacs TO, Krause R, Haber, M, Weissfeld A, Siepman N, et al. A comparison therapy of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998; 158: 1651-56.

  89. Calvet X, Garcia N, Lopez T, Gispert JP, Gene E, Roque M. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxicillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-9.

  90. Vakil N, Lanza F, Schartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004; 20: 99-107.

  91. Moayyedi P, Feltbower R, Rocombe W, Mason S, Atha P, Brown J, Dowell AC. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat program. Aliment Pharmacol Ther 2000; 14(6): 719-28.

  92. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26.

  93. De Francesco V, Zullo A, Margiotta M, Marangi O, Burattini P, Berloco P, et al. Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-14.

  94. Cutler AF, Schubert TT. Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9.

  95. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. The Cochrane database of systematic reviews. The Cochrane Collaboration 2007; Vol 1.

  96. Gisbert JP, Morena F. Systematic review and meta-analysis: Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23(1): 35-44.

  97. Saad R, Schoenfeld P, Hyungjin MK, William DC. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006; 3: 488-96.

  98. Pérez R, García MJ, Astrid Z, González MJ, Hernández H, Más JA, et al. Omeprazol y terapia corta con tinidazol-azitromicina anti-Helicobacter pylori en pacientes con úlcera duodenal. Rev Cubana Med 2004; 43: 2-3.

  99. Coelho LG, Leon-Baura R, Quigley EM. Latin-American Consensus Conference on Helicobacter pylori Infection. Am J Gastroenterol 2000; 95: 2688-91.

  100. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? – A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93: 1409-15.

  101. Bochenek WJ, Peters S, Fraga PD, Barth J. Helicobacter pylori pantoprazole eradication (HELPPE) study group. Eradication of H. pylori by 7-day triple therapy regimens combining pantoprazole with clarithromycin, metronidazole or amoxicillin in patients with peptic ulcer disease: results of two double-blinded, randomized studies. Helicobacter 2003; 8: 626-42.




2020     |     www.medigraphic.com